文献速递慢阻肺

慢性阻塞性肺疾病诊断、管理和预防全球策略:GOLD科学委员会2019年报告

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.
PubMed 文献 · Eur Respir J · 2019-05-18

GOLD 2019科学委员会报告基于近期大型随机对照试验证据,阐述了血嗜酸性粒细胞计数作为生物标志物指导COPD吸入糖皮质激素(ICS)精准治疗的潜力,并指出初始治疗与随访期药物治疗需采用不同评估体系,据此更新了GOLD药理治疗推荐。

要点

  • 血嗜酸性粒细胞计数可辅助精准指导有急性加重史COPD患者的ICS治疗。
  • GOLD 2017的ABCD评估算法适用于初始治疗,但随访期使用存在问题。
  • GOLD 2019区分初始与随访药理管理,并据此更新推荐。

核心结论

  • 血嗜酸性粒细胞计数是有潜力用于临床实践指导COPD患者ICS精准治疗的生物标志物。
  • 需要不同的评估体系来指导随访期COPD药理管理。
  • 新证据促使GOLD 2019药理治疗推荐发生改变。

研究设计与样本

  • GOLD科学委员会报告,基于近期大型随机对照试验证据进行阐述。

主要发现

  • 近期临床试验显示较高的血嗜酸性粒细胞计数与COPD患者ICS疗效更大相关。
  • 近期大型随机对照试验提供了ICS和长效支气管扩张剂对急性加重治疗效应的重要新信息。

关键数值与推荐

  • GOLD 2017药理治疗算法基于ABCD评估,可较容易应用于初始就诊的未治疗个体。
  • GOLD 2017算法在已接受维持治疗的随访患者中使用较为困难。
  • 血嗜酸性粒细胞计数可帮助对有急性加重史且已接受适当支气管扩张剂治疗的COPD患者更精准地靶向ICS治疗。

临床怎么用

  • 在初始治疗时可采用基于ABCD评估的GOLD 2017药理治疗算法。
  • 随访期需采用不同体系指导COPD药理管理。
  • 可考虑血嗜酸性粒细胞计数辅助靶向ICS治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic and biological information in order to optimise the therapeutic benefit relative to the possibility of side-effects for each individual. Recent clinical trials have shown that higher blood eosinophil counts are associated with a greater efficacy of inhaled corticosteroids (ICSs) in chronic obstructive pulmonary disease (COPD) patients. Blood eosinophil counts are a biomarker with potential to be used in clinical practice, to help target ICS treatment with more precision in COPD patients with a history of exacerbations despite appropriate bronchodilator treatment.The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 pharmacological treatment algorithms, based on the ABCD assessment, can be applied relatively easily to treatment-naive individuals at initial presentation. However, their use is more problematic during follow-up in patients who are already on maintenance treatment. There is a need for a different system to guide COPD pharmacological management during follow-up.Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations. The new evidence regarding blood eosinophils and inhaled treatments, and the need to distinguish between initial and follow-up pharmacological management, led to changes in the GOLD pharmacological treatment recommendations. This article explains the evidence and rationale for the GOLD 2019 pharmacological treatment recommendations.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Singh D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019. PMID: 30846476. doi:10.1183/13993003.00164-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。